Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report

BRTX
BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report

BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report

BioRestorative Therapies CEO Mark Weinreb Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Jul 25, 2013) - "Millions of people suffer back pain caused by herniated and bulging disc disease. When conventional medical therapies fail, they often resort to surgery for relief, a costly and time-consuming solution for both patients and the medical system. In this interview with The Life Sciences Report, Mark Weinreb, president, CEO and chairman of BioRestorative Therapies Inc. (OTCQB: BRTX), describes how his company's cell therapy process could keep disc disease treatment out of the operating theater.

The Life Sciences Report: Mark, what disease indication are you exactly going after for patients suffering with back pain?

Mark Weinreb: We have developed a novel cellular therapy and therapeutic delivery device for the treatment of bulging and herniated disc disease. We believe we can effectively and safely treat patients using a nonsurgical, minimally invasive procedure that can be performed routinely in a physician's office. This technology could effectively bridge the gap between noninvasive and surgical back procedures. There are at least one million people, annually, in the U.S. who could benefit from this type of procedure with the promise of avoiding surgery. We elected to pursue this market because of the early success we have seen in several patients who have received this treatment.

TLSR: Can you very briefly describe the technology?"

Continue reading this interview with Mark Weinreb: "BioRestorative Therapies Inc. Develops Plug-and-Play Therapy for Bulging and Herniated Disc Disease."

Read more about cell therapy and BioRestorative Therapies Inc. in The Life Sciences Report's in-depth interview with Jason Kolbert of Maxim Group: "Is Cell Therapy the 'Future of Medicine'?"

About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.

Contact Us
Streetwise Reports, LLC - The Life Sciences Report
Brandon Fung
Email: Email Contact
Tel: 707-981-8107



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today